Journal of Clinical and Aesthetic Dermatology

OCT 2017

An evidence-based, peer-reviewed journal for practicing clinicians in the field of dermatology

Issue link: http://jcadonline.epubxp.com/i/900562

Contents of this Issue

Navigation

Page 10 of 55

Aktipak ™ (erythromycin and benzoyl peroxide) Gel, 3%/5% PATIENT-BLENDED ACNE THERAPY MIXES FRESH Pocket-sized, dual-chamber pouch 1 with an 18-month shelf life from the date of manufacture. 2 PRESCRIBE AKTIPAK ™ FOR YOUR ACTIVE ACNE PATIENTS INDICATIONS AND USAGE AKTIPAK ™ (erythromycin and benzoyl peroxide) Gel, 3%/5% is indicated for the topical treatment of acne vulgaris. IMPORTANT SAFETY INFORMATION Contraindications: AKTIPAK ™ is contraindicated in those individuals who have shown hypersensitivity to any of its components. Precautions: For topical use only; not for ophthalmic use. Concomitant topical acne therapy should be used with caution because a possible cumulative irritancy effect may occur, especially with the use of peeling, desquamating or abrasive agents. If severe irritation develops, discontinue use and institute appropriate therapy. The use of antibiotic agents may be associated with the overgrowth of nonsusceptible organisms. If this occurs, discontinue use and take appropriate measures. Avoid contact with eyes and all mucous membranes. Pregnancy: It is not known whether AKTIPAK ™ can cause fetal harm when administered to a pregnant woman. AKTIPAK ™ should be given to a pregnant woman only if clearly needed. It is not known whether the ingredients of AKTIPAK ™ are excreted in human milk. Therefore, caution should be exercised when erythromycin is administered to a nursing woman. Pediatric Use: The safety and effectiveness of AKTIPAK ™ in pediatric patients below 12 years of age have not been established. Adverse Reactions: The most frequently reported adverse events reported in clinical trials include: dry skin, application site reaction, blepharitis, pruritus, and photosensitivity. Please see the Brief Summary of Full Prescribing Information on the next page. You are encouraged to report negative side effects of prescription drugs to the FDA. Visit http://www.fda.gov/Safety/MedWatch/default.htm or call 1-800-FDA-1088. To learn more about how AKTIPAK ™ is patient-blended, visit aktipak.com. 60 S I N G L E - D O S E P O U C H E S P E R C A R T O N ™ References: 1. Aktipak ™ (erythromycin and benzoyl peroxide) Gel, 3%/5% [package insert]. Wayne, PA: Cutanea Life Sciences, Inc.; 2017. 2. Data on fi le, Cutanea Life Sciences, Inc. 2017. ©2017 Cutanea Life Sciences, Inc. All rights reserved. Wayne, PA 19087 AKT019A 10/17 Aktipak ™ and Cutanea are registered trademarks of Cutanea Life Sciences, Inc.

Articles in this issue

Links on this page

Archives of this issue

view archives of Journal of Clinical and Aesthetic Dermatology - OCT 2017